CA2792036A1 - Polymorphe d'acide 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylique - Google Patents

Polymorphe d'acide 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylique Download PDF

Info

Publication number
CA2792036A1
CA2792036A1 CA2792036A CA2792036A CA2792036A1 CA 2792036 A1 CA2792036 A1 CA 2792036A1 CA 2792036 A CA2792036 A CA 2792036A CA 2792036 A CA2792036 A CA 2792036A CA 2792036 A1 CA2792036 A1 CA 2792036A1
Authority
CA
Canada
Prior art keywords
febuxostat
crystalline form
ketone
reaction mixture
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2792036A
Other languages
English (en)
Inventor
Sarbjot Singh Sokhi
Asok Nath
Nitin Tandon
Mohan Prasad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of CA2792036A1 publication Critical patent/CA2792036A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2792036A 2010-03-04 2011-02-24 Polymorphe d'acide 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylique Abandoned CA2792036A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN488DE2010 2010-03-04
IN488/DEL/2010 2010-03-04
PCT/IB2011/050785 WO2011107911A1 (fr) 2010-03-04 2011-02-24 Polymorphe d'acide 2-[3-cyano-4-(2-méthylpropoxy) phényl]-4-méthylthiazole-5-carboxylique

Publications (1)

Publication Number Publication Date
CA2792036A1 true CA2792036A1 (fr) 2011-09-09

Family

ID=43881251

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2792036A Abandoned CA2792036A1 (fr) 2010-03-04 2011-02-24 Polymorphe d'acide 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylique

Country Status (4)

Country Link
EP (1) EP2542540A1 (fr)
AU (1) AU2011222462A1 (fr)
CA (1) CA2792036A1 (fr)
WO (1) WO2011107911A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012038971A2 (fr) 2010-09-24 2012-03-29 Hetero Research Foundation Nouveaux polymorphes de febuxostat
WO2012168948A2 (fr) 2011-06-06 2012-12-13 Hetero Research Foundation Procédé de préparation de fébuxostat
CN104114545B (zh) * 2011-11-15 2018-06-01 迈兰实验室有限公司 用于制备非布索坦多晶型物的方法
CZ27857U1 (cs) 2014-12-12 2015-02-23 Zentiva, K.S. Formulace obsahující tuhý roztok febuxostatu

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0513379T3 (da) 1990-11-30 1996-09-30 Teijin Ltd 2-Arylthiazolderivater og farmaceutisk præparat indeholdende sådanne
ATE449765T1 (de) 1998-06-19 2009-12-15 Teijin Pharma Ltd Polymorphe modifikationen der 2-(3-cyano-4- isobutylphenyl)-4-methyl-5-thiazol-carbonsäure und verfahren zu ihrer herstellung
US7541475B2 (en) 2003-07-30 2009-06-02 Abbott Laboratories Substituted thiazoles
CA2656264C (fr) 2006-06-23 2014-07-08 Teijin Pharma Limited Methode de production de polymorphes cristallins d'acide 2-(3-cyano-4-(2-methylpropyl)oxyphenyl)-4-methylthiazole-5-carboxylique
CN101139325B (zh) 2006-09-07 2010-05-12 上海医药工业研究院 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸晶型及其制备方法
CN1970547B (zh) 2006-12-07 2011-04-06 重庆医药工业研究院有限责任公司 非布司他的晶型及其制备方法
CN100546985C (zh) 2007-06-29 2009-10-07 上海华拓医药科技发展股份有限公司 非布他特微晶及其组合物
CN101412700B (zh) 2007-10-19 2011-06-08 上海医药工业研究院 非布司他的晶型及其制备方法
CN101386605B (zh) 2008-10-23 2010-09-08 中国科学院上海药物研究所 非布司他新型晶体及其制备方法

Also Published As

Publication number Publication date
WO2011107911A1 (fr) 2011-09-09
AU2011222462A1 (en) 2012-09-27
EP2542540A1 (fr) 2013-01-09

Similar Documents

Publication Publication Date Title
JP7079527B2 (ja) 環内チアミジノアミド－アリールアミド系化合物及びｂ型肝炎を治療するためのその用途
CN109311832B (zh) 沃替西汀的帕莫酸盐及其晶型
CA2375017C (fr) Chlorhydrate de compose heterocyclique fusionne
WO2010083752A1 (fr) Febuxostat de haute pureté et son procédé de préparation
CN109310674B (zh) 醛糖还原酶抑制剂及其使用方法
US20110112164A1 (en) Novel polymorphs and processes for their preparation
JP2000072773A (ja) プリン誘導体
CN103052637B (zh) 醛糖还原酶抑制剂及其用途
ES2575000T3 (es) Proceso mejorado para la preparación de ambrisentano
JP2008273956A (ja) レボフロキサシンおよびその形態の調製
EP2536699A2 (fr) Sels essentiellement purs de fébuxostat et leurs procédés de préparation
CA2480352A1 (fr) Polymorphes de lansoprazole et procedes de preparation de ces derniers
CA2792036A1 (fr) Polymorphe d'acide 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylique
AU2012241378A1 (en) Febuxostat solid dispersion
CA1244431A (fr) Derives de phenypiperazine, et leur production
US10385017B2 (en) Pyrrole compound, compositions and process for preparation thereof
WO2011080651A2 (fr) Formes polymorphes de fébuxostat
CN1863799B (zh) 治疗糖尿病和脂质紊乱的色原烷羧酸衍生物
JP2011526615A (ja) ３−ピロール置換２−インドリノン誘導体の調製
JP2001039976A (ja) 縮合複素環化合物の塩酸塩
KR101919642B1 (ko) 피페라진 유도체, 이를 제조하는 방법, 및 인슐린 저항성의 치료에서 이의 용도
AU2009286521A1 (en) Novel polymorphs of sunitinib and processes for their preparation
JP2002220336A (ja) 縮合複素環化合物の塩酸塩を含有する糖尿病の予防薬、治療薬
CA2566803A1 (fr) Processus de sechage pour preparer un famciclovir solide cristallin
JP2010159293A (ja) ５−アミノサリチル酸のアゾ誘導体のナトリウム塩

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20140225